Third from right in the front row: Director Xuejun Yang
On May 30, the 20th Annual Meeting of the Asian Society for Neuro-oncology (ASNO) was held in Shanghai. The event was co-hosted by the Asian Society for Neuro-oncology (ASNO), the Chinese Society of Neuro-oncology (CSNO), the National Center for Neurological Disorders, Huashan Hospital, and the Department of Neurosurgery and National Center at Huashan Hospital, Fudan University. Professor Xuejun Yang, Director of Neurosurgery-Beijing Tsinghua Changgung Hospital, was unanimously elected Vice President and President-Elect of ASNO. He will serve as President of ASNO in 2028–2029.
As Chair of the Chinese Society of Neuro-oncology (CSNO), Xuejun Yang delivered a speech at the opening ceremony, warmly welcoming experts and scholars from Asia and around the world, as well as representatives from the Society for Neuro-oncology (SNO), the European Association of Neuro-Oncology (EANO), and other international organizations. Yang emphasized that neuro-oncology research in China is increasingly integrated into the global system and has made continuous progress in international clinical trials and innovative treatment strategies. He noted that collaboration and support from international societies such as ASNO have greatly advanced the discipline. He also paid tribute to the foundational contributions of Academicians Liangfu Zhou, Xiuwu Bian, and Tao Jiang. Finally, he highlighted the significance of this congress as a platform for sharing scientific achievements and promoting regional cooperation, expressing the hope that cross-border exchanges would help address the complex challenges in neuro-oncology and improve patient outcomes worldwide.
During the meeting, Yang delivered two keynote presentations, including one titled Tumor Treating Fields (TTFields) for Glioblastoma: In-Depth Analysis of Recent Clinical Breakthroughs, in which he shared the latest progress and clinical practice in China. This study is the largest observational study of TTFields for glioblastoma in the Chinese population to date. Its findings are consistent with global randomized controlled trials and previous real-world studies in China, and it has contributed to revisions of the China Anti-Cancer Association guidelines for integrative diagnosis and treatment of glioma.
At Yang’s suggestion and under his organization, the conference also featured a special session on international collaboration among neuro-oncology societies. In addition, Kai Zhang, Associate Chief Physician of Neurosurgery-Beijing Tsinghua Changgung Hospital, delivered a presentation titled Mixed Reality in Neuro-oncology: The Tsinghua Experience, which reviewed the applications of mixed reality technology in neurosurgery. He outlined the long-term collaboration between Yang’s research group and Professor Guangzhi Wang’s team at the School of Biomedical Engineering, Tsinghua University, which has led to advances in neuro-navigation display and mixed reality technology. Two PhD students from Yang’s team, Xisen Wang and Jiahe Guo, also presented posters at the meeting.
